Home/Pipeline/mRNA-1273 (Spikevax)

mRNA-1273 (Spikevax)

COVID-19

ApprovedCommercial

Key Facts

Indication

COVID-19

Phase

Approved

Status

Commercial

Company

Moderna

About Moderna

Moderna, Inc. is a biotechnology company that harnesses the fundamental role of mRNA to translate genes into proteins to develop a new generation of transformative medicines for patients. The company created one of the most effective COVID-19 vaccines and has built a diverse development pipeline of mRNA medicines across multiple therapeutic areas. Moderna's platform approach enables rapid development of new treatments and vaccines by programming cells to produce therapeutic proteins.

View full company profile

Therapeutic Areas

Infectious Diseases Oncology Rare Diseases Cardiovascular Disease

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
Remdesivir (Veklury)	Gilead Sciences	Approved	Commercial
Investigational Oral COVID-19 Antiviral	Shionogi	Clinical	Active
ZyCoV-D	Zydus Lifesciences	Approved	Commercial
BBIBP-CorV	Sinopharm	Approved	Commercial
SARS-CoV-2 Neutralizing Antibodies	Adaptive Biotechnologies	Discovery	Candidates identified
Covovax™	Novavax	Approved/Commercial	WHO EUL-approved
LY-CoV555 (Bamlanivimab)	AbCellera	Emergency Use Authorization (Past)	Program Completed
ARCT-154 (Bivalent)	Arcturus Therapeutics	Phase 1/2	Active
LUNAR-COV19 (ARCT-021)	Arcturus Therapeutics	Phase 1/2	Completed
Paxlovid (Nirmatrelvir) Manufacturing Enzyme	Codexis	Commercial	Completed Supply